Development and validation of direct RT-LAMP for SARS-CoV-2

Abu Naser Mohon[1], Jana Hundt[1], Guido van Marle[1], Kanti Pabbaraju[2], Byron Berenger[2,3], Thomas Griener[3], Luiz Lisboa[3], Deirdre Church[3,4,5], Markus Czub[6], Alexander Greninger[7], Keith Jerome[8], Cody Doolan[9], Dylan R. Pillai [1,3,4,5]

1. Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, AB, Canada
2. Alberta Public Health Laboratory, Calgary, AB, Canada
3. Clinical Section of Microbiology, Alberta Precision Laboratories, Calgary, AB, Canada
4. Department Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
5. Department of Medicine, University of Calgary, Calgary, AB, Canada
6. Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
7. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
8. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
9. Illucidx Inc., Calgary, AB, Canada

Abstract

We have developed a reverse-transcriptase loop mediated amplification (RT-LAMP) method targeting genes encoding the Spike (S) protein and RNA-dependent RNA polymerase (RdRP) of SARS-CoV-2. The LAMP assay achieves comparable limit of detection as commonly used RT-PCR protocols based on artificial targets, recombinant Sindbis virus, and clinical samples. Clinical validation of single-target (S gene) LAMP (N=120) showed a positive percent agreement (PPA) of 41/42 (97.62%) and negative percent agreement (NPA) of 77/78 (98.72%) compared to reference RT-PCR. Dual-target RT-LAMP (S and RdRP gene) achieved a PPA of 44/48 (91.97%) and NPA 72/72 (100%) when including discrepant samples. The assay can be performed without a formal extraction procedure, with lyophilized reagents which do need cold chain, and is amenable to point-of-care application with visual detection.

Corresponding author: Dylan Pillai MD, PhD, 9-3535 Research Road NW, 1W-416
Calgary, AB, Canada, T2L2K8, drpillai@ucalgary.ca, T: 403-770-3338, F: 403-770-3347

31 **Introduction**

32 Over the last several decades, we have witnessed the rise of both known and novel viruses, including
33 human immunodeficiency virus (HIV), SARS coronavirus (SARS-CoV), MERS-CoV, influenza H1N1, Ebola
34 virus (EBOV), Dengue (DENV), Chikungunya (CHIK), Zika (ZIKV), and most recently 2019 novel
35 coronavirus (SARS-CoV-2/COVID-19)(1). Most of these emerging viral infections have been triggered by a
36 direct zoonotic (animal-to-human) transmission event or enhancement, proliferation and spread of
37 vectors such as the mosquito in new geographic areas. In December 2019 and early January 2020, a
38 cluster of pneumonia cases from a novel coronavirus, SARS-CoV-2, was reported in Wuhan, China (2–4).

39 SARS-CoV-2 has now resulted in a global pandemic with the epicentre at the time of writing in Europe
40 and North America (5). A common theme in the public health response to COVID19 and similar threats is
41 the lack of rapidly deployable testing in the field to screen large numbers of individuals in exposed areas,
42 international ports of entry, and testing in quarantine locations such as the home residences, as well as
43 low-resourced areas (6). This hampers case finding and increases the number of individuals at risk of
44 exposure and infection. With the ease of travel across continents, delayed testing and lack of screening
45 programs in the field, global human-to-human transmission will continue at high rates. These factors
46 make a pandemic very difficult to contain. Early identification of the virus and rapid deployment of a
47 targeted point of care test (POCT) can stem the spread through immediate quarantine of infected
48 persons(7). We used existing viral genome sequences to develop a SARS-CoV-2 loop mediated
49 amplification (LAMP) assay for clinical use and evaluated whether an extraction-free and instrument-
50 free approach could be achieved(8, 9). POCT requires portability and low complexity without reliance on
51 sophisticated extraction and read-out instrumentation. Furthermore, LAMP relies on an alternate set of
52 reagent chemistry that does not depend on or hinder critical elements of the RT-PCR supply chain which

53 is now under duress (10). Our group has previously demonstrated the utility of LAMP for other
54 infectious agents like malaria and dengue (11–13).

55 **Materials and Methods**

56 *Patient samples and Ethics*

57 Clinical samples used in this study were standard nasopharyngeal (NP) swabs in viral transport medium
58 (VTM). Specifically, archival samples were sourced from the University of Washington, Seattle, USA and
59 extracted viral RNA from the Alberta Public Health Laboratory. Ethical approval for use of the archived
60 samples was obtained from the Conjoint Health Research Ethics Board (CHREB) of the University of
61 Calgary (REB20-0402). The use of de-identified specimens was deemed non-human subject work by the
62 University of Washington Institutional Review Board (IRB).

63 *LAMP primer design*

64 Genomic sequences (cDNA) of the SARS-CoV-2 were retrieved from the GenBank database
65 (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/) and multiple sequence alignment analysis
66 (https://www.ebi.ac.uk/Tools/msa/clustalo/) was conducted with other related viruses. From the
67 multiple sequence alignment, several regions unique to the SARS CoV-2 were identified using our own
68 algorithms developed in collaboration with Illucidx Inc. (Calgary, AB). LAMP primer sets were designed
69 targeting unique regions of the Spike (S) protein gene, RNA-dependent RNA Polymerase gene (RdRP),
70 and parts of the Open Reading Frame (ORF) 1a/b. Five sets of LAMP primers were selected for
71 laboratory analysis, where Set 1 and Set 2 targeted the non-structural protein (nsp) 3 region in the
72 ORF1a/b gene and S protein gene, respectively; and Sets 3, 4, and 5 were designed to amplify different
73 regions of RdRP gene of SARS CoV-2 (Table 1). For the external LAMP amplification control, primers
74 were used against bacteriophage MS2 as previously described (14).

75 *Design of artificial viral target for LAMP assay verification*

76 Four fragments of specific SARS-Co-V2 regions (ORF1ab (nsp 3,10-11), RdRP (nsp 12), and spike (S)) were
77 synthesized by SGI-DNA Inc. (San Diego, CA). Fragments were ligated to make one large concatenated
78 DNA template using the BioXP3200 (SGI-DNA, San Diego, CA) automated Gibson assembly system. The
79 final template was 1097 base pairs long containing concatenated ORF1a/b (nsp 3)-Spike protein-RdRP
80 (nsp 12) - ORF1a/b (nsp 10-11) fragments together with flanking plasmid sequence in that order.

81 *Reverse transcription PCR (RT-PCR) assays used in this study*

82 The RT-PCR assays used in this study were performed according to previous publications for the E
83 gene(15) and N2 gene(16). The E gene RT-PCR was performed with modification according to the Alberta
84 Public Health Laboratory reference method (17). Five (5) µL of input template was used to perform the
85 RT-PCR reactions on the same day when RT-LAMP was performed. A maximal Ct value cut-off of 40 was
86 used to determine positivity for all RT-PCR reactions.

87 *LAMP assay conditions*

88 The single-target LAMP reaction was conducted using a combination of Warmstart Rtx Reverse
89 Transcriptase (New England Biolab, Whitby, ON) with *Bst 2.0* Warmstart DNA Polymerase (New England
90 Biolab, Whitby, ON). In a 25 µL LAMP reaction mixture, 1.6 µM F1P and B1P, 0.8 µM LPF and LPB, 0.2 µM
91 F3 and B3 primer concentrations, 8mM $MgSO_4$, 1.4 mM dNTPs, 8 unit of *Bst* 2.0 WarmStart® DNA
92 Polymerase and 7.5 unit of Warm Start® reverse transcriptase were used. The assay was optimized with
93 pre-addition of 0.5µL of 50X SYBR green (Invitrogen, Burlington, ON) in the 25 µL reaction mixture. For
94 all LAMP experiments, 10 µL of template was used in the 25 µL reaction mixture. For dual-target LAMP,
95 identical reagent composition was used except the primers (6 per target) that were added at double
96 concentration and one half the volume for each primer set. Amplification was measured through
97 increased relative fluorescence units (RFU) per minute in the CFX-96 Real-Time PCR detection system

98 (Bio-Rad, Mississauga, ON) or fluorescence values on the QuantStudio 5 RT system (ThermoFisher,
99 Toronto, ON). RFU values above 100 on the CFX-96 instrument or greater than 100,000 on the
100 QuantStudio 5 instrument were considered positive when associated with a typical amplification curve
101 before a 30-minute reaction time. Each primer set was used to amplify the artificial viral DNA target at
102 different temperature (61°C, 63°C, and 65°C) for a maximum LAMP assay run time of 40 minutes.

103 *Visual detection of the LAMP without instrumentation*

104 A positive LAMP assay was detected visually by the pre-addition of 0.5µL colorimetric fluorescence
105 indicator (CFI). CFI was made up of the combination of 0.7% (v/v) 10000X Gelgreen (Biotium, Freemont,
106 CA) in 12 mM Hydroxynapthol blue resuspended in dH_20 (Sigma-Aldrich, Oakville, ON). After the 30-
107 minute LAMP reaction time, the tubes were exposed to blue LED light using a Blue Light Transilluminator
108 (New England Biogroup, Atkinson, NH) to visualize the green fluorescence.

109 *Lyophilized LAMP without the need for cold chain*

110 In order to determine if the LAMP primers and master mix could be lyophilized, oligonucleotides were
111 shipped to Pro-Lab Diagnostics (Toronto, Canada) and lyophilized with GspSSD2 isothermal master
112 mixture (Optigene, UK). The lyophilized primer, enzyme, master mix combination was hydrated in 15 µL
113 of resuspension buffer (Pro-Lab Diagnostics) to which 10 µL of the sample was added. Both direct LAMP
114 (see method described later) and kit-based RNA extractions were performed in this way.

115 *Limit of detection studies*

116 Limit of detection of the LAMP assay was evaluated in three different ways. Initially, copy number of the
117 synthesized DNA fragment was determined by comparing concentration and molecular weight.
118 Subsequently, the template solution was serially diluted to achieve a range from 5,000,000 to 5 copies
119 per reaction. These serially diluted templates were tested by all primers sets. Secondly, the extracted

120 RNA from one patient specimen was 10-fold serially diluted and tested with the LAMP assay and two RT-
121 PCR assays used by reference laboratories targeting both the E gene(15) and N2 gene(16). Finally, the
122 artificial template containing the targeted sequences of interest was cloned into Sindbis Virus (SV) viral
123 vector system (SINrep5) containing green fluorescent protein (EGFP) and then transfected into BHK-21
124 cell lines(18),(19). An approximate estimation of the viral titer was determined by comparing EGFP
125 expressing foci forming units in BHK-21 as described previously. EGFP forming units ranging from 10^6 –
126 10^8/mL were obtained for various recombinant virus stocks. Maintenance of the SARS/CoV2-targetted
127 sequences in the recombinant virus was confirmed using RT-PCR with primers targeting the flanking SV
128 sequences. Virus particles were serially diluted from 100 to 0.001 SV EGFP forming units per μL, and
129 RNA was extracted with the QiaAmp Viral RNA extraction kit (Qiagen, Toronto, ON). Extracted RNA was
130 subjected to TURBO™ DNase (ThermoFisher, Toronto, ON) digestion. Dilutions were subjected to LAMP
131 reactions as described above.

132 *Validation using clinical samples*

133 In total, 42 RT-PCR-positive clinical (n=32), contrived (n=10), and 78 negative NP swab samples were
134 tested in the single-target S gene LAMP validation study. In the negative panel, four common human
135 coronavirus RNA (strain 0C43, NL63, 229E, and HKU1), respiratory syncytial virus (RSV), and Influenza
136 H1N1 clinical samples were included to evaluate the specificity of the test. Contrived samples were
137 generated by inoculating the artificial gene DNA construct described earlier into VTM from NP swabs.
138 Extraction of RNA from clinical samples was performed using the NUCLISENS easyMAG system
139 (Biomerieux, Durham, NC) or QIAamp Viral RNA Mini Kit (Qiagen, Toronto, ON) depending on specimen
140 source. All samples in the set were tested simultaneously using the E gene RT-PCR described above and
141 S gene LAMP (primer set 2). Discrepant analysis was performed by performing the CDC N2 gene(16) RT-
142 PCR assay. For the LAMP assay, 10 μL of the RNA extract was used for each reaction. A second validation

143 study was performed for the dual-target LAMP (S gene and RdRP). Here, RT-PCR-positive clinical (n=34),
144 contrived (n=10), and 72 negative NP swab samples were tested. All LAMP reactions for the clinical
145 validation studies was performed using the combination of Warmstart Rtx Reverse Transcriptase with
146 Bst 2.0 Warmstart DNA Polymerase as described earlier.

147 *Direct LAMP assay without formal extraction*

148 A direct LAMP assay was also conducted to establish an extraction-free approach. In this scheme, the
149 LAMP reaction mixture was prepared without the enzymes. 9.5 µL reaction mixture containing all
150 reagents except the enzymes was added to 14 µL of the 10-fold serially diluted NP VTM sample. For
151 direct LAMP, VTM must be diluted 1:10 (v/v) with dH_20 prior to addition. The mixture was then heated
152 at 95°C for 3, 5, and 10 minutes to both inactivate virus and presumptively release viral RNA. Finally, *Bst*
153 2.0 WarmStart® DNA Polymerase (1 µL) and Warm Start® reverse transcriptase (0.5 µL) were directly
154 added to the reaction mixture and the LAMP assay was carried out as above. Due to evaporative loss,
155 boil steps should have excess volume to ensure adequate input template for LAMP reactions.

156 *In silico analysis of primer combinations to determine cross-reactivity*

157 A blast search alignment (https://blast.ncbi.nlm.nih.gov/Blast.cgi) for primers in set 2 (spike gene) and
158 set 3 (RdRP gene) were performed against a critical list of infectious agents that cause upper respiratory
159 tract infections. A nucleotide local alignment using BLASTn with the default parameters was performed
160 against the National Center of Biotechnology Information (NCBI) Nucleotide database.

161 **Results**

162 *Verification of SARS-CoV-2 LAMP primer sets on artificial gene targets*

163 In order to determine the limits of detection of the five LAMP primer sets designed for SARS-CoV-2,
164 experiments were conducted using an artificial gene target construct. Three targets (Figure 1) selected

165 were the Spike (S) protein gene, the RNA-dependent RNA polymerase (RdRP) region (nsp 12), and nsp 3
166 region in the open reading frame (ORF) 1a/b protein encoding gene sequence. Figure 2 shows the
167 amplification curves for the five primer sets used in this study. Based on time to positivity, primer sets 1,
168 2, and 3 demonstrated the fastest positive reaction time, suggesting optimal performance in the LAMP
169 assay at 50 copies of the artificial target per reaction. When tested at 5 copies per reaction, primer set 2
170 targeting the S gene showed the best limit of detection. An *in silico* analysis of primer set 2 (S gene) and
171 set 3 (RdRP) demonstrated no significant sequence alignment cross-reactivity with known upper
172 respiratory tract infectious pathogens (data not shown).

173 *Visual detection of SARS-CoV-2 LAMP amplification*

174 An advantage of LAMP is the ability to detect amplification with the naked eye either via the use of
175 colorimetric or fluorescent dyes. To test this, LAMP was conducted using the S gene LAMP primer set
176 using the artificial gene target. Figure 3 shows a positive test based on fluorescent detection using a blue
177 light emitting diode (LED). A serial dilution between 50 x 10^7 and 5 copies per reaction of the artificial
178 gene construct is shown with a limit of detection of 50 copies per reaction obtained. The LAMP assay
179 using enzyme GspSSD2 was also performed using a lyophilized master mix. Studies were performed with
180 both kit-based RNA extracted clinical samples as well as using the direct LAMP method described later.
181 These data showed that amplification occurred up to a 1000-fold dilution of a clinical sample with the
182 direct LAMP method (data not shown).

183 *Limit of detection studies using recombinant Sindbis virus (SV) containing SARS-CoV-2 targets*

184 In order to determine LOD based on viral titer, recombinant RNA viral vector from Sindbis virus (SV)
185 containing SARS-CoV-2 targets was generated. LAMP was performed using Set 2 (S gene) alone and in
186 combination with Set 3 (RdRP region (nsp 12)). The primer sets in question achieved a LOD of 0.1-1.0 SV
187 EGFP forming units per μL for the S gene alone and the dual-target LAMP amplifying both S and RdRP

188 genes in a single reaction (Table 2). One SV EGFP focus forming unit (FFU) roughly corresponds to 1.0
189 infectious viral particle given the assumption that one virus particle infects one cell.

190 *Direct LAMP detection of SARS-CoV-2 without formal extraction*

191 Given extraction reagent supply chain shortages, we tested the ability of LAMP using the S gene to
192 amplify a SARS-CoV-2 positive nasopharyngeal swab specimen without a formal extraction procedure.
193 The VTM was heated at 95°C for 3, 5 and 10 minutes and then subjected to the S gene LAMP procedure
194 in a serial dilution experiment. This experiment was performed in a head-to-head comparison with the
195 same specimen tested after formal extraction. Figure 4 demonstrates that amplification occurred with
196 direct LAMP up to a dilution of 100,000-fold with a 95°C for 3 minutes heat step in a single experiment.
197 Table 3 shows the data for direct LAMP compared to LAMP and RT-PCR from RNA extracts in triplicate
198 experiments. Reproducible amplification with direct LAMP (95°C for 3 minutes) occurred at a dilution
199 factor of 1,000-fold, whereas LAMP from an RNA extract was successful reproducibly at a dilution of
200 100,000-fold.

201 *Limit of detection studies using SARS-CoV-2 LAMP on nasopharyngeal swab clinical samples*

202 Serial dilution experiments were conducted using a single positive SARS-CoV-2 nasopharyngeal swab
203 specimen. The viral transport media (VTM) was diluted serially between 10 to 1,000,000-fold. The
204 dilutions were tested in triplicate to determine the results of LAMP and two reference RT-PCR methods
205 (Envelope [E] gene and Nucleocapsid [N] 2 gene). Both RT-PCR and the RT-LAMP (S gene) amplified the
206 target up to a dilution of 100,000 in a head-to-head comparison, suggesting equal LOD (data not shown).
207 The same experiment was conducted comparing E gene RT-PCR to RT-LAMP (dual-target S and RdRP
208 gene) as well as a direct RT-LAMP (dual-target S and RdRP gene) without formal extraction (boil method)
209 on a separate specimen. These data are shown in Figure 5 and Table 4. Reproducible amplification

210 occurred at 1000-fold dilution for RT-PCR (E gene) and RT-LAMP. Direct-LAMP amplified reproducibly at
211 a 100-fold dilution for this sample.

212 *Clinical validation of SARS-CoV-2 LAMP using nasopharyngeal swab samples*

213 A sample set of nasopharyngeal swabs (n=108) from COVID-positive, COVID-negative, together with
214 samples for other respiratory viruses were used to validate the S gene LAMP primer set (Table 5). Given
215 no gold standard exists, percent positive agreement (PPA) and negative percent agreement (NPA) were
216 calculated. Reference methods included RT-PCR (E gene and N2 gene) methods employed by reference
217 laboratories. Using the RT-PCR (E gene) as a reference standard, there was 41/42 (97.62% (95% CI 87.43
218 - 99.94)) PPA and 77/78 (98.72% (95% CI 93.06 - 99.97)) NPA for the S gene LAMP. No cross-reactivity
219 was observed for human coronaviruses (HCoV) OC43, 229E, NL63, and HKU1 or influenza virus A (H1N1)
220 pdm09. Resolution of discrepant results (Table 6) revealed that one falsely positive LAMP result was
221 positive based on the original RT-PCR result reported at the time of clinical testing and therefore
222 represented a true positive that may be due to sample decay in storage. The second falsely negative
223 sample was positive by all methods including the RdRP LAMP primer set and was deemed a false
224 negative in the final analysis. In order to eliminate the concern for S gene false negatives, dual-target S
225 and RdRP LAMP was performed to increase clinical sensitivity. This second clinical sample set
226 intentionally included low positive (high Ct value) specimens. Table 7 demonstrates PPA of 44/48
227 (91.67% (95% CI 80.02 - 97.68)) and NPA 72/72 (100.00% (95% CI 95.01 - 100.00)) for the dual LAMP
228 compared to the RT-PCR E gene reference method. Discrepant analysis (Table 8) revealed that all four
229 falsely negative samples by LAMP were in fact positive by the CDC N2 RT-PCR, confirming the false
230 negative status. The four discrepant specimens were repeated with single-target S gene LAMP and were
231 also negative.

232

233 **Discussion**

234 The global pandemic with SARS-CoV-2 has resulted in the need for diagnostic test development at a
235 scale never seen before. Rapid deployment of validated laboratory-developed diagnostic tests or
236 commercial tests was essential to the containment of the virus as it allows for self-quarantine measures
237 to be imposed in a strategic fashion before widespread community transmission occurs (6, 7) .
238 Diagnostic tests have to be analytically sensitive in order to not to miss any cases in the acute phase of
239 viremia (11). As such, NAATs serve this purpose. In particular, RT-PCR has been employed as the primary
240 diagnostic counter-measure (20). However, reagent supply chains for key items are under immense
241 pressure. Local solutions to reagent sources have become paramount because barriers to trade of these
242 selected items have been a concern.

243 We noted that a one false negative occurred with single-target LAMP (S gene) for a lower Ct value
244 sample that may be due to genetic polymorphism at key residues where LAMP primers bind. This issue
245 was overcome by using two targets (S and RdRP genes) simultaneously. The single and dua-target RT-
246 LAMP test for SARS-CoV-2 has comparable analytical sensitivity and achieved excellent agreement with
247 the reference method. We noted that at high Ct value (>35), and presumably low-level infection, E gene
248 RT-PCR identified specimens that LAMP did not. This suggests the LOD of the RT-PCR used in this study
249 may be superior to LAMP for these low positives. However, we note that samples with E gene RT-PCR Ct
250 values greater than 35 are relatively rare (~1%) at our reference laboratory (our unpublished
251 observations). Increasing LAMP reaction times may reduce false negatives, but also lead to spurious
252 amplification. The clinical relevance of these low positives is still not well understood and could
253 represent early infection during the incubation period, late infection after the initial viral peak, or
254 asymptomatic carriage. The transmissibility of these low positives to others is also not well understood.
255 Moreover, if we assume an overall prevalence of 5%, the negative predictive value of LAMP is 99.56%

256 (95% CI 98.89 - 99.83) and positive predictive value is 100%. These values clearly support the use of
257 LAMP as an alternative NAAT.

258 LAMP does not rely on the same reagents as RT-PCR and thus alleviates pressure on key supply chain
259 items. The LAMP method is amenable to high throughput testing in either 96-well or 384-well. The assay
260 is also able to detect SARS-CoV-2 in VTM without the need for a kit-based RNA extraction method
261 relying on commercial reagents. However, we noted a 2-log drop in analytical sensitivity when direct
262 LAMP was performed following this heat step. The drop in analytical sensitivity will only affect low-level
263 viral load specimens. This is still within a good range compared to RT-PCR using RNA isolation. We
264 believe that addition of a buffer to stabilize the RNA-enzyme complex in the LAMP reaction may further
265 enhance this extraction-free approach. This needs to be tested. The heat step at 95°C for 3 minutes
266 should significantly inactivate the virus permitting safe operation of the assay in a Class II biosafety
267 cabinet (21). Taken together, these data support the use of LAMP chemistry as an alternate method for
268 laboratory developed NAATs.

269 Our studies with a LAMP enzyme called GspSSD2 also provided encouraging results. These data
270 demonstrated that lyophilized GspSSD2 and reagents are able to amplify SARS-CoV-2 directly from a
271 specimen without a kit-based RNA extraction. Additionally, visual detection with a simple blue LED light
272 is able to discriminate positive from negative. These features are particularly useful for resource-limited
273 settings without sophisticated laboratory infrastructure or where the cost of or access to kit-based
274 reagents and equipment are prohibitive. Further studies are required to clinically validate this low-cost
275 approach.

276 Limitations of the study include not testing other sample types such as alternate swabs, nasal washes,
277 oropharyngeal samples, sputum, or stool. This work is ongoing with a special emphasis on swab-free
278 testing. Also formal SARS-CoV-2 viral titers were not calculated in the limit of detection studies.

279 Nevertheless, LAMP presents a much needed alternative approach to SARS-CoV-2 diagnostic testing that
280 is available for deployment immediately in a LDT format as it relies on other key reagents that do not
281 cannibalize RT-PCR reagents. Ultimately, the aim is to port LAMP chemistry on a stand-alone microfluidic
282 device POCT to be deployed in the community, either at ports of entry, homes, pharmacies, or resource-
283 limited settings.

284 **Acknowledgments**

285 Dr. Ranmalee Amarasekara for expert technical assistance, Daniel Castaneda Mogollon for performing
286 bioinformatics analysis, and Omar Abdullah for research analytical support.

287 **Funding Statement**

288 Funding for this study was obtained from the Canadian Institutes for Health Research (NFRFR-2019-
289 00015, DRP) and Genome Canada (DRP), and from the M.J. Murdock Charitable Trust (KRJ).

290 **Conflicts of Interest**

291 ANM and DRP have a patent on LAMP technology. CD is an employee of Illucidx Inc.

292

293

294

295

296

297

298

299 **References**

300 1. Reperant LA, Osterhaus ADME. 2017. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
301 Vaccine 35:4470–4474.

302 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang
303 N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu
304 H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF,
305 Cowling BJ, Yang B, Leung GM, Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of Novel
306 Coronavirus-Infected Pneumonia. N Engl J Med 382:1199–1207.

307 3. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D,
308 Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F,
309 Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new
310 coronavirus of probable bat origin. Nature 579:270–273.

311 4. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan M-L,
312 Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z. 2020. A new coronavirus
313 associated with human respiratory disease in China. Nature 579:265–269.

314 5. CDC COVID-19 Response Team. 2020. Severe Outcomes Among Patients with Coronavirus
315 Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep
316 69:343–346.

317 6. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S, Yansouni CP.
318 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative
319 Review. Ann Intern Med.

320 7. Nguyen T, Duong Bang D, Wolff A. 2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the
321 Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines 11.

322 8. Forster P, Forster L, Renfrew C, Forster M. 2020. Phylogenetic network analysis of SARS-CoV-2
323 genomes. Proc Natl Acad Sci U S A.

324 9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F,
325 Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ,
326 Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. 2020. Genomic characterisation and
327 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond
328 Engl 395:565–574.

329 10. Ivanov D. 2020. Predicting the impacts of epidemic outbreaks on global supply chains: A
330 simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case. Transp Res Part E
331 Logist Transp Rev 136:101922.

332 11. Sigera PC, Amarasekara R, Rodrigo C, Rajapakse S, Weeratunga P, De Silva NL, Huang CH, Sahoo
333 MK, Pinsky BA, Pillai DR, Tissera HA, Jayasinghe S, Handunnetti S, Fernando SD. 2019. Risk prediction for
334 severe disease and better diagnostic accuracy in early dengue infection; the Colombo dengue study.
335 BMC Infect Dis 19:680.

336 12. Mohon AN, Getie S, Jahan N, Alam MS, Pillai DR. 2019. Ultrasensitive loop mediated isothermal
337 amplification (US-LAMP) to detect malaria for elimination. Malar J 18:350.

338 13. Girma S, Cheaveau J, Mohon AN, Marasinghe D, Legese R, Balasingam N, Abera A, Feleke SM,
339 Golassa L, Pillai DR. 2018. Prevalence and epidemiological characteristics of asymptomatic malaria based
340 on ultrasensitive diagnostics: A cross-sectional study. Clin Infect Dis Off Publ Infect Dis Soc Am.

341 14. Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW,
342 Mead DA, Chander Y. 2016. Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus
343 Directly From Blood. J Infect Dis 214:S234–S242.

344 15. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S,
345 Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der Veer B, van den Brink S, Wijsman L,
346 Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten
347 C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill Bull Eur Sur
348 Mal Transm Eur Commun Dis Bull 25.

349 16. 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.
350 Centers for Disease Control and Prevention.

351 17. https://www.albertahealthservices.ca/assets/wf/lab/wf-lab-bulletin-COVID-19-test-
352 performance.pdf.

353 18. van Marle G, Ethier J, Silva C, Mac Vicar BA, Power C. 2003. Human immunodeficiency virus type
354 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector.
355 Virology 309:61–74.

356 19. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. 1993. Sindbis virus expression vectors:
357 packaging of RNA replicons by using defective helper RNAs. J Virol 67:6439–6446.

358 20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H, Jerome
359 KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection Assays using Seven
360 Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol.

361 21. Darnell MER, Subbarao K, Feinstone SM, Taylor DR. 2004. Inactivation of the coronavirus that
362 induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods 121:85–91.

363

364

365

366

367

368 **Figures**

369

370 Figure 1: Map of the gene fragments from SARS-Co-V2 (Genbank ID MT2078.1) that were used for
371 synthesizing the genetic construct template. Fragments of ORF1a/b [nsp 3] (3064-3285), ORF1a/b [nsp
372 10-11] (13328-13622), ORF1a/b RdRP [nsp 12] (15258-15445), and Spike gene (22153-22368) were
373 concatenated into a single artificial construct.



374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395 Figure 2: Limit of detection of RT-LAMP primer sets designed to detect the SARS-CoV-2 artificial DNA
396 construct. These data are representative of an experiment performed in triplicate at (A) 500 and (B) 50
397 copies. Amplification curves for all 5 primer sets are shown: Set 1 (ORF1ab); Set 2 (S gene); and Set 3, 4,
398 and 5 (RdRP). Based on these experiments, a cut off 30 minutes reaction time was determined for
399 specific amplification. Fluorescence (QuantStudio 5) on the y-axis is plotted in relation to reaction time
400 (minutes).
401



402

403

404

405

406

407

408

409

410

411

412

413

414

415 Figure 3: Photograph of S gene RT-LAMP (Set 2) performed on the artificial DNA construct. Fluorescence
416 can be detected by naked eye after excitation of gel green in the reaction with a blue LED light. A serial
417 10-fold dilution is shown from 5 x 10^7 copies to 5 copies of the gene construct in this representative
418 experiment (left to right). The last two tubes on the right are negative template controls. A reaction time
419 was set at 30 minutes.
420

421



422

423

424

425

426

427

428

429

430

431

432

433

Figure 4: Single-target (S gene) RT-LAMP amplification of SARS-CoV-2 spike gene from NP swab sample (E gene Ct 21.29) using a simple heat step. A representative direct LAMP experiment is compared to a kit-based extracted RNA (A) for serial dilutions of the neat sample. Heat inactivation without formal extraction is shown in (B) 95°C for 3 minutes (C) 95°C for 5 minutes and (D) 95°C for 10 minutes. Relative fluorescence units (CFX-96) on the y-axis is plotted in relation to reaction time (minutes).



454 Figure 5: Serial dilution studies of a clinical sample (NP swab in VTM, E gene Ct 25.6) comparing the limit
455 of detection of Envelope (E) gene RT-PCR (n=6), S gene + RdRP gene RT-LAMP (n=9) and S gene + RdRP
456 gene direct RT-LAMP (n=9). Cycle threshold (Ct) value (RT-PCR) or time in minutes (LAMP) shown on y-
457 axis. No virus was detected at a dilution of 1 x 10^5 from the original neat sample. Standard deviation of
458 the mean indicated in error bars if more than two values existed.
459

460

461
462
463



464
465
466
467
468

469

470

471

472

473

474

475

476

477

478

479 **Tables:**

480 Table 1: Primer sets used in this study to perform RT-LAMP. All 5 primer sets are shown: Set 1 (ORF1a/b,
481 nsp3); Set 2 (S gene); and Set 3, 4, and 5 (RdRP).

482

Primer name	Sequence
S1-F3	AGTTTGAGCCATCAACTCA
S1-B3:	TGAACCTCAACAATTGTTTGA
S1-F1P	CAGGTTGAAGAGCAGCAGAAGTGTACTGAAGATGATTACCAAGG
S1-B1P	AGCAAGAAGAAGATTGGTTAGATGATGTCTGATTGTCCTCACTG
S1-LPF	GGCACCAAATTCCAAAGGT
S1-LPB	AACTGTTGGTCAACAAGACGG
S2-F3	ATTCTAAGCACACGCCTAT
S2-B3	GAAGATAACCCACATAATAAGCT
S2-F1P	ACCTATTGGCAAATCTACCAATGGTTTAGTGCGTGATCTCCCT
S2-B1P	ATCACTAGGTTTCAAACTTTACTTGCCTGTCCAACCTGAAGAAGA
S2-LPF	TTCTAAAGCCGAAAAACCCTG
S2-LPB	CATAGAAGTTATTTGACTCCTGGTG
S3-F3	CACCTTATGGGTTGGGATT
S3-B3	AACATATAGTGAACCGCCA
S3-F1P	GTTTGCGAGCAAGAACAAGTGAATGTGATAGAGCCATGCC
S3-B1P	ATACAACGTGTTGTAGCTTGTCACACATGACCATTTCACTCAA
S3-LPF	GGCCATAATTCTAAGCATGTTA
S3-LPB	ATTAGCTAATGAGTGTGCTCAAGTA
S4-F3	ACATGCTTAGAATTATGGCC
S4-B3	GCTTGACAAATGTTAAAAACACT
S4-F1P	TTGAGCACACTCATTAGCTAATCTATCACTTGTTCTTGCTCGCA
S4-B1P	GAGTGAAATGGTCATGTGTGGCGCATAAGCAGTTGTGGCA
S4-LPF	GACAAGCTACAACACGTTGTATGT

S4-LPB	ACTATATGTTAAACCAGGTGGAACC
S5-F3	ATGGCCTCACTTGTTCTT
S5-B3	TAACATTGGCCGTGACAG
S5-F1P	TTGAGCACACTCATTAGCTAATCTATGCTCGCAAACATACAACG
S5-B1P	GTCATGTGTGGCGGTTCACTACACTATTAGCATAAGCAGTTG
S5-LPF	ACGGTGTGACAAGCTACAACA
S5-LPB	CCAGGTGGAACCTCATCAGGAG

483

484

485

486

487 Table 2: RT-LAMP assay results on serially diluted recombinant SV virus containing the artificial construct
488 now expressed as RNA. Positive tested replicates/total number of replicates is shown in relation to the
489 approximate viral titer for both single-target (S gene) and dual-target (S and RdRP gene) LAMP reactions.

490

Approximate viral titer/µL	S gene Single-target RT-LAMP	S gene and RdRP gene Dual-Target RT-LAMP
100	3/3	3/3
10	3/3	3/3
1	3/3	3/3
0.1	2/3	2/3
0.01	0/3	1/3
0.001	0/3	0/3

491 Table 3: Single-target (S gene) RT-LAMP assay results on a NP swab VTM sample (E gene Ct 21.29) containing SARS-Co-V2 compared to RT-LAMP
492 and RT-PCR after kit-based RNA extraction. Positive tested replicates/total number of replicates for a single representative triplicate experiment
493 is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample. Kit-based extraction is compared to direct RT-LAMP
494 procedures including a heat step.

495

Sample dilution factor	E gene RNA extract RT-PCR	N2 gene RNA extract RT-PCR	RT-LAMP RNA extract	Direct RT-LAMP 10 min/95°C	Direct RT-LAMP 5 min/95°C	Direct RT-LAMP 3 min/ 95°C
10	3/3	3/3	3/3	3/3	3/3	3/3
100	3/3	3/3	3/3	3/3	3/3	3/3
1000	3/3	3/3	2/3	1/3	2/3	2/3
10000	3/3	3/3	3/3	0/3	0/3	1/3
100000	2/3	2/3	2/3	0/3	0/3	1/3

496

497

498

499

500

501

502

503

504

505 Table 4: Dual-target RT-LAMP (S and RdRP gene) assay results on a NP VTM sample (E gene Ct 25.6) containing SARS-Co-V2 compared to RT-PCR
506 after kit-based RNA extraction and directly from a sample. Positive tested replicates/total number of replicates from repeated triplicate
507 experiments is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample.

508

Sample dilution factor	E gene RNA extract RT-PCR	Dual RT-LAMP RNA extract	Direct dual RT-LAMP 3 min/ 95°C
10	6/6	9/9	9/9
100	6/6	9/9	9/9
1000	6/6	5/9	1/9
10000	1/6	1/9	0/9
100000	0/6	0/9	0/9

509 Table 5: Validation of RT-LAMP (S gene) compared to RT-PCR (E gene) for clinical samples (NP swabs),
510 contrived samples, and negative control samples. PPA - positive percent agreement; NPA - negative
511 percent agreement

512

RT-LAMP (S gene)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	41	1	42
Negative	1	77	78
Total	42	78	120
PPA	97.67% (95% CI 87.43 - 99.94)		
NPA	98.72% (95% CI 93.06 - 99.97)		

513

514

515 Table 6: Discrepant analysis for single-target (S gene) RT-LAMP from the clinical validation data
516 set.

517

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S gene)	RT-LAMP (RdRP)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample 4	Positive	Negative	Positive	Negative	Negative	N/A	Positive
Sample 7	Positive	Positive	Negative	Positive	Positive	26.8	Positive

518

519

520 Table 7: Validation of dual-target RT-LAMP (S gene and RdRP genes) using a validation set of
521 clinical samples. PPA - positive percent agreement; NPA - negative percent agreement

RT-LAMP (S + RdRP)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	44	0	44
Negative	4	72	76
Total	48	72	120
PPA	91.67% (95% CI 80.02 - 97.68)		
NPA	100.00% (95% CI 95.01 - 100.00)		

522 Table 8: Discrepant analysis for dual-target (S + RdRP gene) RT-LAMP for samples with high Ct
523 values from the clinical validation data

524

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S + RdRP gene)	RT-LAMP (S gene)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample A7	Positive	Positive	Negative	Negative	Positive	38.36	Positive
Sample A8	Positive	Positive	Negative	Negative	Positive	36.19	Positive
Sample B7	Positive	Positive	Negative	Negative	Positive	36.41	Positive
Sample D5	Positive	Positive	Negative	Negative	Positive	35.39	Positive

525